問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2023-09-19

李柏昕
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

67Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李柏昕

List

83Cases

2024-12-01 - 2027-12-31

Phase II

Active
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    injection

Participate Sites
10Sites

Recruiting10Sites

2025-06-09 - 2029-11-26

Phase III

Not yet recruiting
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation

  • Condition/Disease

    COPD with Type 2 inflammation

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2025-10-01 - 2027-08-31

Phase II

Active
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D

  • Condition/Disease

    RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D

  • Test Drug

    tablets

Participate Sites
5Sites

Not yet recruiting5Sites

2025-05-01 - 2030-04-30

Phase III

Active
A Global, Multicenter, Randomized, Open?label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  • Condition/Disease

    Extensive-stage small cell lung cancer (ES-SCLC)

  • Test Drug

    sacituzumab govitecan

Participate Sites
9Sites

Recruiting9Sites

2024-08-30 - 2028-03-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2022-04-05 - 2024-07-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-02-26 - 2037-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2023-11-01 - 2035-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    V940 (mRNA-4157)KEYTRUDAR

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2024-04-15 - 2033-12-31

Phase III

Active
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    injection

Participate Sites
12Sites

Not yet recruiting11Sites

Recruiting1Sites

1 2 3 4 5 6 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB